Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof
OwnerGeraldine Grouard-Vogel, Olivier Dhellin +2inventors
InventorsGeraldine Grouard-Vogel, Olivier Dhellin, Bernard Fancet, Pierre Vandepapeliere
Life of this patent
Estimating the term…
Abstract
An immunogenic product includes TNFα coupled with KLH, wherein the TNFα is strongly inactivated, which means that the product shows less than 30% of cytolytic activity and/or an inactivation factor of more than 15000, in the conditions of TEST A. An emulsion and a vaccine including the product and methods for preparing the immunogenic product are also described.
Claims23
1-19. (canceled)
An immunogenic product comprising TNFα coupled with KLH, wherein the TNFα is strongly inactivated, which means that the product at a concentration of 100 ng/ml shows less than 30% of cytolytic activity and/or an inactivation factor of more than 15000, in the conditions of TEST A.
A method for preparing a product comprising TNFα coupled with KLH, wherein the TNFα is strongly inactivated, which means that the product at a concentration of 100 ng/ml shows less than 30% of cytolytic activity in the conditions of TEST A, comprising the steps of:
- a) mixing together (i) purified TNFα, (ii) purified Keyhole limpet hemocyanin and (iii) glutaraldehyde
- b) removing compounds having a molecular weight of less than 10 kDa
- characterized in that after step b) the following steps are performed:
- c) adding formaldehyde in a concentration/time of reaction condition ranging from at least 60 mM for at least 240 hours to at least 120 mM for at least 144 hours
- d) blocking the reaction with formaldehyde by adding a quenching compound selected from (i) a reducing agent and (ii) an amino acid selected from the group consisting of lysine and glycine and mixture thereof,
- e) collecting said immunogenic product.
A method for preparing a product comprising TNFα coupled with KLH, wherein the TNFα is strongly inactivated, which means that the product at a concentration of 100 ng/ml shows less than 30% of cytolytic activity in the conditions of TEST A, comprising the steps of:
- a) mixing together (i) purified TNFα, (ii) purified Keyhole limpet hemocyanin and (iii) glutaraldehyde
- b) removing compounds having a molecular weight of less than 10 kDa
- c) adding formaldehyde in a concentration/time of reaction condition ranging from at least 60 mM for at least 144 hours to at least 250 mM for at least 96 hours,
- characterized in that
- in step a) glutaraldehyde is applied at a concentration of at least 20 mM during more than 18 hours, the reaction with glutaraldehyde is stopped by adding a quenching compound, preferably a quenching compound that is selected from (i) a reducing agent and (ii) an amino acid selected from the group consisting of lysine and glycine and mixture thereof, and then the product is collected.
A kit comprising,
- at least one vial containing an immunogenic product comprising TNFα coupled with KLH, wherein the TNFα is strongly inactivated, which means that the product at a concentration of 100 ng/ml shows less than 30% of cytolytic activity and/or an inactivation factor of more than 15000, in the conditions of TEST A,
- at least one vial containing water for injection, and
- at least one vial containing adjuvant,
- and means for mixing the immunogenic product and the water in order to obtain an aqueous solution, and for contacting said solution to the adjuvant, and for emulsifying the mixture of the aqueous solution with the adjuvant, said kit further including at least one needle.
A medical device comprising an immunogenic product comprising TNFα coupled with KLH, wherein the TNFα is strongly inactivated, which means that the product at a concentration of 100 ng/ml shows less than 30% of cytolytic activity and/or an inactivation factor of more than 15000, in the conditions of TEST A.
Dependencies are inferred from the claim text.